

Daily Calcium May Protect Against Colon Polyps

BY ROBERT FINN
San Francisco Bureau

ANAHEIM, CALIF. — Long-term daily supplementation with 1,200 mg elemental calcium protects against the development of adenomas and hyperplastic polyps, John A. Baron, M.D., reported at the annual meeting of the American Association for Cancer Research.

For up to 5 years after the end of a randomized, placebo-controlled clinical trial, patients who had received calcium supplementation had a 35% reduction in the risk of adenomas and a 41% reduction in the risk of hyperplastic polyps, said Dr. Baron of Dartmouth Medical School, Lebanon, N.H.

"Personally, I believe that calcium does reduce the risk of adenomas very clearly and probably reduces the risk of cancer itself as well," he said. "There's one issue that needs to be resolved before calcium can be strongly recommended more generally, and that is that some people believe that calcium supplements may increase the risk of prostate cancer."

Because of that issue, Dr. Baron said he would shy away from making broad recommendations. "For targeted recommendations for women, I think you could say that calcium is very likely to be effective and very unlikely to have significant toxicity, with the proviso that you'll prob-

ably need to take it for a long time before you see an effect on colorectal cancer."

The original study randomized 930 patients with a history of precancerous adenoma to 1,200 mg of daily elemental calcium for 4 years or to a placebo. That study demonstrated a 19% overall reduction in polyp formation and a 28% reduction in advanced adenomas.

The current study reported on up to 8 years of follow-up data on these same patients after completion of the randomized

controlled trial. Of the 865 subjects who survived the original trial, Dr. Barron and his colleagues obtained follow-up information on 822, and 597 had colonoscopies at least 6 months after the end of the trial.

The calculated risk reductions were adjusted for age, sex, study center, the interval between the final study exam and the first follow-up colonoscopy, and participants' reported use of calcium supplementation after the original study.

"We conclude that calcium supplemen-

tation is effective in reducing the risk of colorectal adenomas after the cessation of supplementation," Dr. Baron said. "There's no rebound at all. In fact there appears to be a delayed, more pronounced suppression of colorectal neoplasia during the 5 years after treatment."

He suggested that calcium may be exerting its effects at an early stage of the cancer process, and those effects only become manifest with a reduction in visible lesions years later. ■

Elevated Serum Bile Acid Level Linked to ICP

VIENNA — An elevated serum bile acid level is a highly reliable indicator of intrahepatic cholestasis of pregnancy in a woman who presents with itching and excoriated skin lesions late in gestation, Christina M. Rudolph, M.D., reported at the annual meeting of the European Society for Dermatological Research.

In her series of 75 patients who presented with pruritic skin changes to a specialized dermatology clinic for pregnant women, the lowest serum bile acid level among the 11 patients with intrahepatic cholestasis of pregnancy (ICP)—7.3 $\mu\text{mol/L}$ —was markedly greater than the highest value among women with other pruritic conditions, said Dr. Rudolph of the University of Graz, Austria.

The distinction is important because intrahepatic cholestasis of pregnancy, if untreated, is associated with higher risks of stillbirth and preterm delivery, she noted.

Other dermatologic diagnoses made in this cohort were atopy-related skin changes, specific dermatoses of pregnancy, psoriasis, pityriasis rosea, and drug reaction. The mean serum bile acid level in these women was 2.3 $\mu\text{mol/L}$, with a range of 0.4-4.5 $\mu\text{mol/L}$.

In contrast, the range of serum bile acid levels in women with ICP was 7.3-138 $\mu\text{mol/L}$, with an average value of 37.4 $\mu\text{mol/L}$.

—Bruce Jancin



*Zolpidem tartrate worldwide.

AMBIEN is the #1 prescribed sleep agent in the US²

AMBIEN is indicated for the short-term treatment of insomnia. In elderly or debilitated patients, or patients with hepatic dysfunction, treatment should be initiated with a 5-mg dose and patients closely monitored. Due to its rapid onset of action, patients should take AMBIEN right before going to bed and when ready for sleep. Patients should not take AMBIEN unless they are prepared to get a full night's sleep (7 to 8 hours) to avoid residual effects. Until they know how it will affect their physical or mental performance upon awakening, patients should not drive or operate hazardous machinery after taking AMBIEN or any other sleep medication. During short-term treatment with AMBIEN, the most commonly observed adverse effects in controlled clinical trials were drowsiness (2%), dizziness (1%), and diarrhea (1%). Because individuals with a history of addiction or substance abuse are at increased risk of habituation and dependence, they should be under careful surveillance when receiving AMBIEN or any other hypnotic. AMBIEN is classified as a Schedule IV controlled substance. Sedative hypnotics have produced withdrawal signs and symptoms following abrupt discontinuation. Hypnotics should generally be limited to 7 to 10 days of use, and reevaluation of the patient is recommended if they are taken for more than 2 to 3 weeks. Prescriptions for AMBIEN should not exceed a 1-month supply.

Please see brief summary of prescribing information on back.

sanofi aventis

Sanofi-Synthelabo Inc., a member of the sanofi-aventis Group

©2005 Sanofi-Synthelabo Inc.
57-050003

Visit our Web site at www.ambien.com

AMBIEN[®]
(ZOLPIDEM TARTRATE)^{IV}
5-MG & 10-MG TABLETS
Restful nights, refreshed awakenings